chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Cytogenetic analysis, Exposure during pregnancy, Pregnancy test
Clinical narrative: pregnant patient received vaccine; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (pregnant patient received vaccine) in a 37-year-old female patient (gravida 7, para 3) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for COVID-19 vaccination.     The patient's past medical history included Secondary infertility (female), Hyperemesis (Pregnancy history) on 04-Jun-2019, Hyperemesis (Pregnancy history) on 25-Jan-2017, Hyperemesis (Pregnancy history) on 03-Jan-2014, Torn muscle (unclear if torn back muscle was maternal medical history during pregnancy or infant) on 03-Jan-2014 and Spontaneous abortion (genetic abnormality, chromosomal issue with fetus.) on 28-Dec-2012. Concurrent medical conditions included Seasonal allergy (seasonal-grass), Topical adhesive allergy (adhesives), Allergy (cedar), Hypothyroidism, Osteoarthritis, Irritable bowel syndrome and Asthma (Asthma post-partum). Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID) for Hypothyroidism, L-THEANINE, PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] and CALCIUM CARBONATE, COLECALCIFEROL (VITAMIN D 2000) for an unknown indication.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 27-Sep-2020 and the estimated date of delivery was 04-Jul-2021. On 03-Mar-2021, the patient experienced EXPOSURE DURING PREGNANCY (pregnant patient received vaccine). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-second week of the pregnancy.  On 03-Mar-2021, EXPOSURE DURING PREGNANCY (pregnant patient received vaccine) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 28-Oct-2020, Pregnancy test: (Positive) Pregnancy test positive. On 12-Dec-2020, Cytogenetic analysis: (normal) Genetic testing normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Pyrexia
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (Chills) and PYREXIA (Low grade fever) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, the patient experienced CHILLS (Chills) and PYREXIA (Low grade fever). At the time of the report, CHILLS (Chills) and PYREXIA (Low grade fever) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication use was provided.   No treatment information was provided.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Lymphadenopathy, Sinusitis
Clinical narrative: pressure from eyebrow between eyes, and cheekbone; headache-left side; swollen lymph nodes in neck /behind ear left side; This spontaneous case was reported by a consumer and describes the occurrence of SINUSITIS (pressure from eyebrow between eyes, and cheekbone), HEADACHE (headache-left side) and LYMPHADENOPATHY (swollen lymph nodes in neck /behind ear left side) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021, the patient experienced HEADACHE (headache-left side) and LYMPHADENOPATHY (swollen lymph nodes in neck /behind ear left side). On 10-Mar-2021, the patient experienced SINUSITIS (pressure from eyebrow between eyes, and cheekbone). At the time of the report, SINUSITIS (pressure from eyebrow between eyes, and cheekbone), HEADACHE (headache-left side) and LYMPHADENOPATHY (swollen lymph nodes in neck /behind ear left side) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Vaccination complication
Clinical narrative: felt herself "miserable"; nausea; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (felt herself "miserable") and NAUSEA (nausea) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016M20A and J13L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 24-Feb-2021, the patient experienced VACCINATION COMPLICATION (felt herself "miserable") and NAUSEA (nausea). On 25-Feb-2021, VACCINATION COMPLICATION (felt herself "miserable") and NAUSEA (nausea) had resolved.
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Chills, Fatigue, Headache, Pain
Clinical narrative: Low grade fever 99.6 ºF - 100.8 ºF; Chills; Slight headache; Feeling fatigued; Had cramps on their stomach; Soreness; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL PAIN UPPER (Had cramps on their stomach), PAIN (Soreness), PYREXIA (Low grade fever 99.6 ºF - 100.8 ºF), CHILLS (Chills) and HEADACHE (Slight headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Mar-2021, the patient experienced PAIN (Soreness). On 10-Mar-2021, the patient experienced ABDOMINAL PAIN UPPER (Had cramps on their stomach), PYREXIA (Low grade fever 99.6 ºF - 100.8 ºF), CHILLS (Chills), HEADACHE (Slight headache) and FATIGUE (Feeling fatigued). On 04-Mar-2021, PAIN (Soreness) had resolved. At the time of the report, ABDOMINAL PAIN UPPER (Had cramps on their stomach), PYREXIA (Low grade fever 99.6 ºF - 100.8 ºF), CHILLS (Chills), HEADACHE (Slight headache) and FATIGUE (Feeling fatigued) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 10-Mar-2021, Pyrexia: low grade 99.6 ºF - 100.8 ºF.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Low grade fever 99.6 ºF - 100.8 ºF; Chills; Slight headache; Feeling fatigued; Had cramps on their stomach; Soreness; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL PAIN UPPER (Had cramps on their stomach), PAIN (Soreness), PYREXIA (Low grade fever 99.6 ºF - 100.8 ºF), CHILLS (Chills) and HEADACHE (Slight headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Mar-2021, the patient experienced PAIN (Soreness). On 10-Mar-2021, the patient experienced ABDOMINAL PAIN UPPER (Had cramps on their stomach), PYREXIA (Low grade fever 99.6 ºF - 100.8 ºF), CHILLS (Chills), HEADACHE (Slight headache) and FATIGUE (Feeling fatigued). On 04-Mar-2021, PAIN (Soreness) had resolved. At the time of the report, ABDOMINAL PAIN UPPER (Had cramps on their stomach), PYREXIA (Low grade fever 99.6 ºF - 100.8 ºF), CHILLS (Chills), HEADACHE (Slight headache) and FATIGUE (Feeling fatigued) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 10-Mar-2021, Pyrexia: low grade 99.6 ºF - 100.8 ºF.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Sex: M
Vaccine: COVID19
Symptoms: Accidental overdose, Chills, Injection site haemorrhage, Pain
Clinical narrative: Throbbing pain in both arms, pain from fingertips to one side and excruciating pain; Excruciating pain and bleeding; Overdose accidental; 6 chills in one minute; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Throbbing pain in both arms, pain from fingertips to one side and excruciating pain), INJECTION SITE HAEMORRHAGE (Excruciating pain and bleeding), ACCIDENTAL OVERDOSE (Overdose accidental) and CHILLS (6 chills in one minute) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016M20A and 003A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 09-Mar-2021, the patient experienced PAIN (Throbbing pain in both arms, pain from fingertips to one side and excruciating pain), INJECTION SITE HAEMORRHAGE (Excruciating pain and bleeding), ACCIDENTAL OVERDOSE (Overdose accidental) and CHILLS (6 chills in one minute). On 09-Mar-2021, ACCIDENTAL OVERDOSE (Overdose accidental) had resolved. At the time of the report, PAIN (Throbbing pain in both arms, pain from fingertips to one side and excruciating pain), INJECTION SITE HAEMORRHAGE (Excruciating pain and bleeding) and CHILLS (6 chills in one minute) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  No treatment information was provided.  Action taken with mRNA-1273 in response to the event "He got invalid dose" was Not applicable and not reported for other events.   Most recent FOLLOW-UP information incorporated above includes: On 10-Mar-2021: Follow-up information received on 10-Mar-2021 included no new information.; Reporter's Comments: This report refers to a case of Accidental overdose for mRNA-1273, lot 003A21A with associated adverse events. Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Dysgeusia, Pain in extremity, Sinusitis
Clinical narrative: arm was sore; salty taste; sinus infection; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm was sore), SINUSITIS (sinus infection) and DYSGEUSIA (salty taste) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 02T520-2A) for COVID-19 vaccination.     No medical history was reported by the reporter.  Concomitant products included CENTRUM SILVER +50 and ZINC for an unknown indication.    On 03-Feb-2021 at 2:00 PM, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, the patient experienced PAIN IN EXTREMITY (arm was sore) and DYSGEUSIA (salty taste). In February 2021, the patient experienced SINUSITIS (sinus infection). The patient was treated with AZITHROMYCIN ongoing since an unknown date for Sinus infection, at a dose of 1 dosage form. On 06-Feb-2021, PAIN IN EXTREMITY (arm was sore) had resolved. In February 2021, SINUSITIS (sinus infection) had resolved. At the time of the report, DYSGEUSIA (salty taste) outcome was unknown.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Inappropriate schedule of product administration, SARS-CoV-2 test positive
Clinical narrative: Past 36 days for second dose; tested positive for Covid-19; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (tested positive for Covid-19) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Past 36 days for second dose) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Mar-2021, the patient experienced SARS-COV-2 TEST POSITIVE (tested positive for Covid-19). On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Past 36 days for second dose). At the time of the report, SARS-COV-2 TEST POSITIVE (tested positive for Covid-19) outcome was unknown and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Past 36 days for second dose) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-Mar-2021, COVID-19: Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia
Clinical narrative: Had a sore arm; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Had a sore arm) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, the patient experienced MYALGIA (Had a sore arm). At the time of the report, MYALGIA (Had a sore arm) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication details was reported. No treatment medication details was reported..   Most recent FOLLOW-UP information incorporated above includes: On 04-May-2021: Additional initial information, outcome provided.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Injection site pain, Vaccination site discolouration
Clinical narrative: injection site turned into greenish bluish in color; pain at injection site/ Sore at injection site; shoulder pain with left arm  and shoulder joint pain; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE DISCOLOURATION (injection site turned into greenish bluish in color), INJECTION SITE PAIN (pain at injection site/ Sore at injection site) and ARTHRALGIA (shoulder pain with left arm  and shoulder joint pain) in a 55-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information provided by the reporter.     On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Mar-2021, the patient experienced INJECTION SITE PAIN (pain at injection site/ Sore at injection site) and ARTHRALGIA (shoulder pain with left arm  and shoulder joint pain). On 09-Mar-2021, the patient experienced VACCINATION SITE DISCOLOURATION (injection site turned into greenish bluish in color). At the time of the report, VACCINATION SITE DISCOLOURATION (injection site turned into greenish bluish in color), INJECTION SITE PAIN (pain at injection site/ Sore at injection site) and ARTHRALGIA (shoulder pain with left arm  and shoulder joint pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant products included VITAMINS. No treatment medication details was reported.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Hyperhidrosis, Pyrexia
Clinical narrative: perfuse sweating; fever of 103; fatigue; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (perfuse sweating), PYREXIA (fever of 103) and FATIGUE (fatigue) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HYPERHIDROSIS (perfuse sweating), PYREXIA (fever of 103) and FATIGUE (fatigue). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency and IBUPROFEN (MOTRIN [IBUPROFEN]) at an unspecified dose and frequency. At the time of the report, HYPERHIDROSIS (perfuse sweating), PYREXIA (fever of 103) and FATIGUE (fatigue) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication details was reported.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site pruritus, Injection site swelling, Peripheral swelling, Pruritus
Clinical narrative: Itching at the injection site; swelling of arm; Redness of injection site; swelling on the injection site; Itching and redness on injection site; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itching at the injection site), PERIPHERAL SWELLING (swelling of arm), INJECTION SITE PRURITUS (Itching and redness on injection site), INJECTION SITE ERYTHEMA (Redness of injection site) and INJECTION SITE SWELLING (swelling on the injection site) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Feb-2021, the patient experienced INJECTION SITE PRURITUS (Itching and redness on injection site) and INJECTION SITE SWELLING (swelling on the injection site). On 10-Mar-2021, the patient experienced PRURITUS (Itching at the injection site), PERIPHERAL SWELLING (swelling of arm) and INJECTION SITE ERYTHEMA (Redness of injection site). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency and Manual therapy (cold ice) for Injection site swelling. At the time of the report, PRURITUS (Itching at the injection site), PERIPHERAL SWELLING (swelling of arm), INJECTION SITE PRURITUS (Itching and redness on injection site), INJECTION SITE ERYTHEMA (Redness of injection site) and INJECTION SITE SWELLING (swelling on the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Maternal exposure during pregnancy, Pain, Rash
Clinical narrative: Felt tired; A very mild rash on chest and neck; Vaccine exposure during pregnancy; Pain was pronounced; This spontaneous prospective pregnancy case was reported by a pharmacist and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy), PAIN (Pain was pronounced), RASH (A very mild rash on chest and neck) and FATIGUE (Felt tired) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010A21A) for COVID-19 vaccination.     No medical history was provided by reporter.  Concomitant products included BENZATROPINE MESILATE (COGENTIN), DOCUSATE, VITAMIN D3, ONDANSETRON HYDROCHLORIDE (ZOFRAN [ONDANSETRON HYDROCHLORIDE]) and MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for an unknown indication.    On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 16-Nov-2020 and the estimated date of delivery was 23-Aug-2021. On 01-Mar-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) and PAIN (Pain was pronounced). On 05-Mar-2021, the patient experienced RASH (A very mild rash on chest and neck). On an unknown date, the patient experienced FATIGUE (Felt tired). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  fifteenth week of the pregnancy.  On 01-Mar-2021, MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) had resolved. On 04-Mar-2021, PAIN (Pain was pronounced) had resolved. At the time of the report, RASH (A very mild rash on chest and neck) and FATIGUE (Felt tired) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment medication details was reported.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Hepatic enzyme increased
Clinical narrative: Elevated Liver enzymes; This spontaneous case was reported by a consumer and describes the occurrence of HEPATIC ENZYME INCREASED (Elevated Liver enzymes) in a 23-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 09-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Feb-2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Mar-2021, the patient experienced HEPATIC ENZYME INCREASED (Elevated Liver enzymes). The patient was treated with NORETHINDRONE ACETATE at an unspecified dose and frequency. At the time of the report, HEPATIC ENZYME INCREASED (Elevated Liver enzymes) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication details was reported. No treatment medication details was reported.
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: Device connection issue, Underdose
Clinical narrative: Adminstered inadequate dose from a leaked syringe/ fluid in vaccine cap less than 1/2 0.5cc vaccine dose was administered; Adminstered inadequate dose from a leaked syringe; This spontaneous case was reported by an other health care professional and describes the occurrence of UNDERDOSE (Adminstered inadequate dose from a leaked syringe/ fluid in vaccine cap less than 1/2 0.5cc vaccine dose was administered) and DEVICE CONNECTION ISSUE (Adminstered inadequate dose from a leaked syringe) in an 88-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, the patient experienced UNDERDOSE (Adminstered inadequate dose from a leaked syringe/ fluid in vaccine cap less than 1/2 0.5cc vaccine dose was administered) and DEVICE CONNECTION ISSUE (Adminstered inadequate dose from a leaked syringe). At the time of the report, UNDERDOSE (Adminstered inadequate dose from a leaked syringe/ fluid in vaccine cap less than 1/2 0.5cc vaccine dose was administered) and DEVICE CONNECTION ISSUE (Adminstered inadequate dose from a leaked syringe) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported. The treatment information was unknown. The patient did not report any adverse event during the one hour observation period.   This case was linked to MOD21-050051 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 21-Jun-2021: Follow up received on 21-Jun-2021 contains No newinformation; Sender's Comments:  MOD21-050051:
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Body temperature increased
Clinical narrative: temperature of 101.7; This spontaneous case was reported by a consumer and describes the occurrence of BODY TEMPERATURE INCREASED (temperature of 101.7) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 09-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Mar-2021, the patient experienced BODY TEMPERATURE INCREASED (temperature of 101.7). At the time of the report, BODY TEMPERATURE INCREASED (temperature of 101.7) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 10-Mar-2021, Body temperature: high (High) 101.7.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Reporter did not allow further contact
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site pain, Pyrexia
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever of 99F) and INJECTION SITE PAIN (Injection site pain) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032M20A and 012M20A) for COVID-19 vaccination. No Medical History information was reported. On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-Mar-2021, the patient experienced PYREXIA (Fever of 99F) and INJECTION SITE PAIN (Injection site pain). At the time of the report, PYREXIA (Fever of 99F) and INJECTION SITE PAIN (Injection site pain) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. No concomitant medication details was reported. No treatment medication details was reported.
Sex: F
Vaccine: COVID19
Symptoms: Acanthoma, Herpes zoster
Clinical narrative: Shingles on leg; Acanthoma (cancer) on her leg; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (Shingles on leg) and ACANTHOMA (Acanthoma (cancer) on her leg) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Feb-2021, the patient experienced HERPES ZOSTER (Shingles on leg) and ACANTHOMA (Acanthoma (cancer) on her leg). At the time of the report, HERPES ZOSTER (Shingles on leg) and ACANTHOMA (Acanthoma (cancer) on her leg) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication details was reported. No treatment medication details was reported.
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills
Clinical narrative: chills; Joint pain; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (chills) and ARTHRALGIA (Joint pain) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004MZ0A) for COVID-19 vaccination.     The patient's past medical history included Rheumatoid arthritis (Takes unspecified RA medications.) since an unknown date.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, the patient experienced CHILLS (chills) and ARTHRALGIA (Joint pain). The patient was treated with PARACETAMOL (TYLENOL) for Pain, at an unspecified dose and frequency. At the time of the report, CHILLS (chills) and ARTHRALGIA (Joint pain) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications included unspecified medication for Rheumatoid arthritis.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Maternal exposure during pregnancy, Pain in extremity, Vaccination site rash
Clinical narrative: rash on injection site; Arm soreness; Pregnant patient received the Moderna vaccine; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm soreness), MATERNAL EXPOSURE DURING PREGNANCY (Pregnant patient received the Moderna vaccine) and VACCINATION SITE RASH (rash on injection site) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was reported.  Concomitant products included ACETYLSALICYLIC ACID (ASPIRIN 81) and MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for an unknown indication.    On 26-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 20-Jul-2020 and the estimated date of delivery was 26-Apr-2021. On 26-Dec-2020, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnant patient received the Moderna vaccine). On 27-Dec-2020, the patient experienced PAIN IN EXTREMITY (Arm soreness). On 02-Jan-2021, the patient experienced VACCINATION SITE RASH (rash on injection site). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-second week of the pregnancy.  On 26-Dec-2020, MATERNAL EXPOSURE DURING PREGNANCY (Pregnant patient received the Moderna vaccine) had resolved. At the time of the report, PAIN IN EXTREMITY (Arm soreness) and VACCINATION SITE RASH (rash on injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment details were reported.   This case was linked to MOD-2021-076246 (Patient Link).
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain
Clinical narrative: back pain has gotten worse; This spontaneous case was reported by a consumer and describes the occurrence of BACK PAIN (back pain has gotten worse) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003A21A) for COVID-19 vaccination.     Concomitant products included IBUPROFEN for Back pain.   On 05-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Mar-2021, the patient experienced BACK PAIN (back pain has gotten worse). At the time of the report, BACK PAIN (back pain has gotten worse) outcome was unknown.            Concomitant medications were not provided by reporter.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Breast swelling, Discomfort, Erythema, Hypoaesthesia, Paraesthesia
Clinical narrative: red numbness; tingling on little toe; red; swelling of breast; lots of discomfort; swelling of hands; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (red), BREAST SWELLING (swelling of breast), DISCOMFORT (lots of discomfort), PERIPHERAL SWELLING (swelling of hands) and HYPOAESTHESIA (red numbness) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 024M20A and 020B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Breast cancer.   On 05-Mar-2021 at 6:30 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 06-Mar-2021, the patient experienced ERYTHEMA (red), BREAST SWELLING (swelling of breast), DISCOMFORT (lots of discomfort) and PERIPHERAL SWELLING (swelling of hands). On 07-Mar-2021, the patient experienced HYPOAESTHESIA (red numbness) and PARAESTHESIA (tingling on little toe). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency and ASPIRIN [ACETYLSALICYLIC ACID] at an unspecified dose and frequency. At the time of the report, ERYTHEMA (red), BREAST SWELLING (swelling of breast), DISCOMFORT (lots of discomfort), PERIPHERAL SWELLING (swelling of hands), HYPOAESTHESIA (red numbness) and PARAESTHESIA (tingling on little toe) outcome was unknown.            It was reported that patient had immune issue . No concomitant medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 09-Jun-2021: Added facility information.Updated patient demographics, batch number and re-challenge field.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling
Clinical narrative: red numbness; tingling on little toe; red; swelling of breast; lots of discomfort; swelling of hands; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (red), BREAST SWELLING (swelling of breast), DISCOMFORT (lots of discomfort), PERIPHERAL SWELLING (swelling of hands) and HYPOAESTHESIA (red numbness) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 024M20A and 020B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Breast cancer.   On 05-Mar-2021 at 6:30 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 06-Mar-2021, the patient experienced ERYTHEMA (red), BREAST SWELLING (swelling of breast), DISCOMFORT (lots of discomfort) and PERIPHERAL SWELLING (swelling of hands). On 07-Mar-2021, the patient experienced HYPOAESTHESIA (red numbness) and PARAESTHESIA (tingling on little toe). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency and ASPIRIN [ACETYLSALICYLIC ACID] at an unspecified dose and frequency. At the time of the report, ERYTHEMA (red), BREAST SWELLING (swelling of breast), DISCOMFORT (lots of discomfort), PERIPHERAL SWELLING (swelling of hands), HYPOAESTHESIA (red numbness) and PARAESTHESIA (tingling on little toe) outcome was unknown.            It was reported that patient had immune issue . No concomitant medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 09-Jun-2021: Added facility information.Updated patient demographics, batch number and re-challenge field.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Gait disturbance
Clinical narrative: Difficulty walking; Chills; Joint on her leg has been hurting; This spontaneous case was reported by a consumer and describes the occurrence of GAIT DISTURBANCE (Difficulty walking), CHILLS (Chills) and ARTHRALGIA (Joint on her leg has been hurting) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, the patient experienced GAIT DISTURBANCE (Difficulty walking), CHILLS (Chills) and ARTHRALGIA (Joint on her leg has been hurting). The patient was treated with PARACETAMOL (TYLENOL) at a dose of unknown. At the time of the report, GAIT DISTURBANCE (Difficulty walking), CHILLS (Chills) and ARTHRALGIA (Joint on her leg has been hurting) outcome was unknown.            Patient was taking other medication.  No treatment medication information was provided.  Action taken with mRNA-1273 in response to the drug was not applicable.
Age: 90.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity, Swelling
Clinical narrative: Pain; Swelling; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Pain) and SWELLING (Swelling) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Pain) and SWELLING (Swelling). At the time of the report, PAIN IN EXTREMITY (Pain) and SWELLING (Swelling) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Developed shingles on left side of body and on his back; A regulatory report was received from a Consumer concerning a 72 years old, male patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and developed shingles on the left side of body and on his back (Herpes zoster).  The patient's medical history includes numerous medical issues and leukemia for 16 years. The relevant concomitant medications reported were also not provided.  On 12 Feb 2021, prior to the onset of the event, the patient received his first dose of two planned vaccine doses of mRNA (Lot number: 031620A) through intramuscular route for prophylaxis of COVID-19 infection.  On 04 Mar 2021, patient developed shingles on the left side of body and on his back. The patient was taken to the clinic and was treated with Famvir 500 mg TID and Cortisone Cream.  No laboratory data was provided.   Action taken with mRNA-1273 in response to the event was not reported.   The outcome of the event, developed shingles on left side of body and on his back, was unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded. However, the patient's underlying medical history of leukemia seems to be a strong confounding factor to the reported event.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Myalgia, Nausea
Clinical narrative: achy; nauseated, thought he was going to throw up; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (achy) and NAUSEA (nauseated, thought he was going to throw up) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013A21A and 013M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-Mar-2021, the patient experienced MYALGIA (achy) and NAUSEA (nauseated, thought he was going to throw up). At the time of the report, MYALGIA (achy) and NAUSEA (nauseated, thought he was going to throw up) outcome was unknown.            No relevant concomitant medications were reported. No treatment information was provided.   Reporter did not allow further contact
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Cellulitis, Erythema, Injection site erythema, Injection site pain, Injection site swelling
Clinical narrative: probably cellulitis; Arm Redness; Pain; Swollen arm; Itchy; Warm to touch; had the reaction at the injection site: swollen, red, itchy and very tender to touch; Injection site very tender to touch; Injection site swollen; Injection site redness; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of CELLULITIS (probably cellulitis), ERYTHEMA (Arm Redness), PAIN (Pain), PERIPHERAL SWELLING (Swollen arm) and PRURITUS (Itchy) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, the patient experienced ERYTHEMA (Arm Redness), PAIN (Pain), PERIPHERAL SWELLING (Swollen arm), PRURITUS (Itchy), SKIN WARM (Warm to touch), VACCINATION SITE PRURITUS (had the reaction at the injection site: swollen, red, itchy and very tender to touch), INJECTION SITE PAIN (Injection site very tender to touch), INJECTION SITE SWELLING (Injection site swollen) and INJECTION SITE ERYTHEMA (Injection site redness). On an unknown date, the patient experienced CELLULITIS (probably cellulitis). The patient was treated with CEFDINIR ongoing from March 2021 for Cellulitis, at a dose of 1 dosage form twice a day. At the time of the report, CELLULITIS (probably cellulitis), ERYTHEMA (Arm Redness), PAIN (Pain), PERIPHERAL SWELLING (Swollen arm), PRURITUS (Itchy), SKIN WARM (Warm to touch), VACCINATION SITE PRURITUS (had the reaction at the injection site: swollen, red, itchy and very tender to touch), INJECTION SITE PAIN (Injection site very tender to touch), INJECTION SITE SWELLING (Injection site swollen) and INJECTION SITE ERYTHEMA (Injection site redness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications included unspecified hormonal medication and thyroid medication.   Most recent FOLLOW-UP information incorporated above includes: On 10-Mar-2021: Initial additional
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Peripheral swelling, Pruritus, Skin warm, Vaccination site pruritus
Clinical narrative: probably cellulitis; Arm Redness; Pain; Swollen arm; Itchy; Warm to touch; had the reaction at the injection site: swollen, red, itchy and very tender to touch; Injection site very tender to touch; Injection site swollen; Injection site redness; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of CELLULITIS (probably cellulitis), ERYTHEMA (Arm Redness), PAIN (Pain), PERIPHERAL SWELLING (Swollen arm) and PRURITUS (Itchy) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, the patient experienced ERYTHEMA (Arm Redness), PAIN (Pain), PERIPHERAL SWELLING (Swollen arm), PRURITUS (Itchy), SKIN WARM (Warm to touch), VACCINATION SITE PRURITUS (had the reaction at the injection site: swollen, red, itchy and very tender to touch), INJECTION SITE PAIN (Injection site very tender to touch), INJECTION SITE SWELLING (Injection site swollen) and INJECTION SITE ERYTHEMA (Injection site redness). On an unknown date, the patient experienced CELLULITIS (probably cellulitis). The patient was treated with CEFDINIR ongoing from March 2021 for Cellulitis, at a dose of 1 dosage form twice a day. At the time of the report, CELLULITIS (probably cellulitis), ERYTHEMA (Arm Redness), PAIN (Pain), PERIPHERAL SWELLING (Swollen arm), PRURITUS (Itchy), SKIN WARM (Warm to touch), VACCINATION SITE PRURITUS (had the reaction at the injection site: swollen, red, itchy and very tender to touch), INJECTION SITE PAIN (Injection site very tender to touch), INJECTION SITE SWELLING (Injection site swollen) and INJECTION SITE ERYTHEMA (Injection site redness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications included unspecified hormonal medication and thyroid medication.   Most recent FOLLOW-UP information incorporated above includes: On 10-Mar-2021: Initial additional
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site induration, Vaccination site pruritus, Vaccination site swelling
Clinical narrative: Itching and swelling on the injection site (looking like a bug bite); Itching and swelling on the injection site (looking like a bug bite); Hardness on the injection site on her right upper arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE INDURATION (Hardness on the injection site on her right upper arm), VACCINATION SITE PRURITUS (Itching and swelling on the injection site (looking like a bug bite)) and VACCINATION SITE SWELLING (Itching and swelling on the injection site (looking like a bug bite)) in a 28-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Mar-2021, the patient experienced VACCINATION SITE INDURATION (Hardness on the injection site on her right upper arm). On 09-Mar-2021, the patient experienced VACCINATION SITE PRURITUS (Itching and swelling on the injection site (looking like a bug bite)) and VACCINATION SITE SWELLING (Itching and swelling on the injection site (looking like a bug bite)). At the time of the report, VACCINATION SITE INDURATION (Hardness on the injection site on her right upper arm), VACCINATION SITE PRURITUS (Itching and swelling on the injection site (looking like a bug bite)) and VACCINATION SITE SWELLING (Itching and swelling on the injection site (looking like a bug bite)) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications included an unspecified asthma inhaler.  Treatment for the events included antihistamine.
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia
Clinical narrative: arm numbness; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (arm numbness) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, the patient experienced HYPOAESTHESIA (arm numbness). At the time of the report, HYPOAESTHESIA (arm numbness) had not resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided.